New Data Analysis Shows Eli Lilly's Drug Leads to Superior Weight Loss Results Compared to Novo Nordisk's Wegovy

Tuesday, 9 July 2024, 10:30

Shares of Novo Nordisk declined by 1.1% following a recent analysis indicating that Eli Lilly's drug, Mounjaro, achieves more rapid and significant weight loss compared to Novo Nordisk's Wegovy. The study, published in JAMA Internal Medicine, compared the weight loss effects of tirzepatide in Mounjaro with semaglutide in Wegovy, providing insights into the efficacy of these obesity treatments.

Yahoo Finance — New Data Analysis Shows Eli Lilly's Drug Leads to Superior Weight Loss Results Compared to Novo Nordisk's Wegovy

Novo Nordisk Shares Downtrend

Novo Nordisk stock witnessed a 1.1% decrease in value after the release of a comparative study between its drug Wegovy and Eli Lilly's Mounjaro.

Study Findings

Eli Lilly's tirzepatide demonstrated faster and more significant weight loss compared to Novo Nordisk's semaglutide in treating obesity.

The analysis, published in JAMA Internal Medicine, evaluated the weight loss rates of both drug formulations.
It indicates a potential effectiveness shift in the market for obesity treatment drugs.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Novo Nordisk Shares Downtrend

Study Findings

Related posts